Background: The purpose of our study was to characterize the causes of death among cancer patients as a function of objectives: (i) calendar year, (ii) patient age, and (iii) time after diagnosis.
Introduction
Cancer accounts for a significant portion of deaths around the world [1] and in the United States (US) [2] [3] [4] . Worldwide, in 2013, cancer killed over 8 million; it has moved from the third leading cause of death in 1990 to the second leading cause of death in 2013, following heart disease [3] . In the United States, during 2013, heart disease was responsible for 611 105 deaths, followed by cancer at 584 881 [4] . Substantial progress has been made since the 1990s in the United States [5] and in Europe [6] with regard to the prevention, diagnosis, and treatment of various cancers. As survivorship from cancer continues to increase [7] , the principal participants of the healthcare field (e.g. patients, providers, and payers) should identify the cancer patients at highest risk of dying, as well as their risk of a particular cause of death.
The purposes of this work are to characterize the causes of death among cancer patients in the United States as a function of (i) calendar year, (ii) patient age, and (iii) time after diagnosis. The results identify the patients who (i) are at lowest risk to die of their cancer; (ii) are at highest risk to die of their cancer; (iii) might profit from intense screening for second cancers; and (iv) are at highest risk of noncancer death (and its causes). Additionally, these findings may identify areas of oncology that would most benefit from further research.
Methods
The analytical strategy can be broken into three components (supplementary Figure S1 , available at Annals of Oncology online). Patients developing invasive cancer, diagnosed between 1973 and 2012, were abstracted from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program [8, 9] . The complete methods and limitations for each objective are described in supplementary Methods, available at Annals of Oncology online. SEER is a network of population-based incident tumor registries from geographically distinct regions in the United States, covering 28% of the US population, including incidence, survival, and treatment (e.g. radiation therapy, surgery, and chemotherapy) [8, 9] . The SEER registry does not code comorbidities, performance status, surgical pathology, margin status, doses, or agents. SEER*Stat 8.2.1 was used for analysis [8] . Patients diagnosed only through autopsy or death certificate were excluded.
The strategy for objective I is shown in supplementary Figure S2 and Table S1 , available at Annals of Oncology online. Death, based on death certificate, was coded as being as due to "index-cancer," (i.e. the cancer originally diagnosed in the patient), "nonindex-cancer" (i.e. a second primary), and "noncancer death" (i.e. death from any medical cause not coded as cancer). To account for discrepancies, for certain sites, deaths attributed to locoregional cancer subsites were included as part of the index-cancer death (supplementary Table S1 , available at Annals of Oncology online).
For objectives II and III, the analysis of death was undertaken according to published methods for suicide [10] including a total of 26 noncancer causes of deaths; the top 13 causes of death were reported, using standardized mortality ratios (SMRs) [8] . SMRs provide the relative risk of death for patients with cancer as compared with all US residents [10, 11] . Data were characterized with SMRs adjusted by age, race, and sex to the US population over the same time. The 95% confidence intervals (CIs) of the SMRs were calculated using SEER*Stat 8.2.1 and Microsoft Excel 15.0.4 (Microsoft, Redmond, WA) [11] [12] [13] . At least 1000 personyears at risk were necessary for each cause of death with respect to cancer type to minimize the CIs (CIs are listed in supplementary Tables S2 and  S3 , available at Annals of Oncology online).
Results

Deaths per calendar year
Index-cancer deaths. Death rates are illustrated in Figure 1 ; individual yearly rates of death are provided in supplementary Figure  S1 and Table S1 , available at Annals of Oncology online. The greatest decrease in index-cancer death (generally from >60% to <30% of patients) was noted (black lines with negative slope in Figure 1 ) among those with cancers of the testis, kidney, bladder, endometrium, breast, cervix, prostate, ovary, anus, colorectum, melanoma, and lymphomas. The high proportions of death due to cancer in the early years of SEER reflect the low risk of death due to causes other than cancer. Notably, patients diagnosed in recent years with cancers that have an indolent course are not represented among these curves because these patients have not yet died of any cause. The majority of deaths among cancer patients in recent years are not due to the index-cancer (Figure 2A) . Among all cancer patients dying from the index-cancer ( Figure 2B ), the most had lung tumors. Index-cancer deaths (all typically > 40%) have been relatively stable among patients with cancers of the liver, pancreas, lung and bronchus, esophagus, brain, and multiple myeloma (MM) (Figure 1 , black lines with near-zero slope).
Nonindex-cancer deaths. Currently, the highest incidence of nonindex-cancer death is among patients with the original/first cancer of the oropharynx, testis, soft tissue, larynx, stomach, and lymphoma (gray lines among graphs in Figure 1 ; all 20%-30%).
Over the entire calendar year session, the greatest increase in nonindex-cancer death (i.e. greatest positive slope among gray lines in Figure 1 ) has been realized among patients with cancers of the gallbladder, prostate, testis, stomach, and Hodgkin's lymphoma (HL). Prostate and breast cancer patients currently experience that highest rate of death due to nonindex-cancers ( Figure 2C ).
Noncancer deaths. Noncancer causes of death (green lines in Figure 1 ) are currently highest (versus index-or nonindex-cancer) in patients with cancers of the colorectum, genitourinary tract (e.g. bladder and kidney), female cancers (e.g. endometrial, cervix, breast, and vulvar), male cancers (e.g. prostate, testicular, and penile), tonsil cancer, melanoma of the skin, and lymphomas. For many of these patients, the risk of dying from a different medical condition has superseded the risk of death from any form of cancer.
The most common cause of noncancer death is generally heart disease (red lines among graphs in Figure 1 ). The highest rates of heart disease-associated death (all 13%-21%) are currently observed among patients with cancers of the prostate, breast, testis, endometrium, larynx, and HL. The primary sites contributing the largest share of noncancer deaths at the inception of the SEER registry, when incidence and prevalence were equivalent, were lung cancer and prostate cancer. The current data, however, show prostate and breast cancer patients contributing the largest share to the overall noncancer mortality rates ( Figure 2D ).
Noncancer death SMRs
Per-patient age group. For objectives II and III, there were 651 287 deaths due to noncancer causes; the plurality of deaths (279 039) were due to heart disease. The rate of noncancer death varied perpatient age group (supplementary Table S2 , available at Annals of Oncology online): those <45 years of age tended to die of "other causes" and "other" infections; older patients died largely of heart disease and "other causes."
SMRs for the leading causes of noncancer death were characterized after diagnosis, binned by age groups (Figure 3 ; supplementary Figure S3 , available at Annals of Oncology online); a heat map table was created among the most common cancers (supplementary Table S4 , available at Annals of Oncology online). Among all SMR plots, SMRs were highest for younger patients, and (although elevated) they typically decreased-almost all P < 0.05. The highest relative increase in SMRs (for the average of all cancers) was noted for nonbacterial infections, parasites, and human immunodeficiency virus infection; and pneumonia and influenza. The cancers with high SMRs tended to be of immunologic/hematologic origin: leukemias, lymphomas, Kaposi's sarcoma, and MM. Additionally, lung and bronchus cancer consistently displayed increased SMRs.
During follow-up. When noncancer deaths were plotted versus time after diagnosis (Figure 4 ; supplementary Figure S5 , available at Annals of Oncology online), heart disease was the leading cause (40% of deaths) for patients at all time points. SMRs for the leading causes of noncancer death were characterized as a function of time after diagnosis (supplementary Figure S6, to die of medical comorbidities, compared with patients with any other type of cancer. Among all SMR plots, the highest relative increase in SMRs (for the average of all cancers) was attributable to nonbacterial infections, parasites, and human immunodeficiency virus infection. Among the patients dying from suicide and selfinflicted injury, those with lung and bronchus cancer had the highest SMR within the first year, followed by breast cancer and testis cancer. Testis cancer patients, however, had the highest persistent risk of suicide and self-inflicted injury.
Discussion
Previous analyses have reported on the causes of death among patients with individual cancers (e.g. prostate [14] and breast [15] ), or among various cancer patients dying of a particular cause of death (e.g. suicide [10] ). The current study is unique in that it characterizes causes of death among 28 individual cancers, from 13 causes of death, as a function of calendar year, follow-up time, and patient age. Thus, the current work is synergistic and the largest of its kind. We report that patients with prostate, breast, and testis cancer are least likely to die of their cancer. Patients with lung, pancreas, and brain tumors are most likely to die of their cancer. Patients with cancer of the oropharynx, larynx, and HL may benefit from screening or early detection of second cancers.
Patients with prostate and breast cancer are at highest risk to die of noncancer death. Noncancer death is most likely due to heart disease, either from treatment or from general risk factors; or infection, likely secondary to treatment.
The analysis helps to identify the patients who are least likely to die of their cancer (e.g. those with cancer of the larynx, stomach, bladder, endometrium, breast, testis, prostate, anus, colorectum, ovary, and melanoma, NHL, and HL). Although the death rate from prostate and breast cancer has declined, the absolute number of patients dying to these diseases remains elevated because of the high incidence of the cancers (Figure 2A ). The observed benefits in index-cancer death rates may come from screening (e.g. prostate-specific antigen [16] or mammography [17] ). Some cancers included in this analysis may be presenting at an earlier stage, when they are curable, increasing the denominator and decreasing the percentage of patients dying of the index-cancer. Benefits in the treatment may also be due to improvements in surgical, radiation, and medical oncology. Most have been incremental, but some have been dramatic [18] .
The study identifies diseases demanding more effective therapies, prevention, and early detection [19] . They may benefit from increased research funding [20] . These sites include cancers of the liver, pancreas, lung and bronchus, nasopharynx, esophagus, brain, and MM (Figure 1) .
Patients who might benefit from screening and more effective treatment of second cancers (Figure 1 , gray lines with positive slopes; Figure 2C ), include those with cancers of the prostate, breast, lung, colorectum, oropharynx, testis, larynx, and HL. There may be a need for effective surveillance of patients after curative treatment of these cancers [21] [22] [23] . Some of these cancers present in the young (e.g. HL and testis); subsequent cancers may be referable to treatment (e.g. breast cancer development after RT for HL) [23] Figure 4 . SMRs for the leading causes of noncancer death were characterized after diagnosis, binned by time periods. An SMR above 1 represents a higher relative risk of death for a particular cause, when compared with the noncancer population. Black lines represent SMRs from all sites; purple from lung and bronchus cancer; blue from prostate cancer; pink from breast cancer; and brown from colorectum. Select cancers with outlier SMRs (green, red, and yellow lines) are also plotted.
tobacco exposure [24] , emphasizing the need for complete cessation. Among other cancers (e.g. ovarian and breast), the risk of a subsequent malignancy may be attributable to another cancer is likely secondary to genetic factors [25] . Indeed, second cancers may simply reflect diseases arising in any aging population. Those at highest risk of noncancer death may largely be divided into two groups: (i) those with chronic comorbid conditions and (ii) acute, iatrogenic, or treatment-induced infections. The most common chronic comorbid conditions are secondary to cardiovascular disease, including heart disease and cerebrovascular diseases. For older patients with common cancers (e.g. breast, prostate, colorectal; per supplementary Tables S1 and S2 and Figures S3 and  S4 , available at Annals of Oncology online), measures to maintain general health are appropriate. Site-specific survivorship guidelines have been published for many malignancies [21, 23, 26, 27] .
The risk of death from a particular cause varies with follow-up time (supplementary Tables S2 and S3 and Figures S5 and S6 , available at Annals of Oncology online). The SMR of suicide increases (versus SMRs of other causes of death), likely because of a high incidence of depression among these patients [28] . These results concur with the findings of a SEER analysis that noted higher suicide rates in cancer survivors [10] . The SMR of Alzheimer's disease rises rapidly in prostate cancer patients, compared with all others, corroborating the work of Nead et al [29] .
One cohort of patients likely to die of noncancer causes is younger patients with hematologic malignancy (e.g. leukemias, lymphomas; per supplementary Figure S4 , available at Annals of Oncology online). These deaths frequently occur within the first year after cancer diagnosis and probably result from treatment. As cure rates for childhood, adolescent, and young adult cancers (e.g. lymphomas and leukemias) have improved, treatment-related deaths now account for a high percentage of all deaths [30] [31] [32] .
This analysis has important limitations. Death due to the indexcancer may be miscoded; typically, the errors in coding are referable to attributing a locoregional relapse to a new cancer or metastasis to an adjacent organ [8, 9] . We arbitrarily grouped deaths from such causes together and are unable to assess the true incidence of such nonindex-cancers (supplementary Figures S1 and S2 and Methods, available at Annals of Oncology online). Some noncancer causes of death may actually be referable to treatment; we attempted to identify them using patient age and time after diagnosis. In addition, "other causes" of death or "other" infections counted among noncancer causes of death are likely due to treatment-related infections. Finally, patients in the SEER database are accrued over time beginning in 1973; thus, patients appear to have a higher risk of death because the number of all cancer patients in the database is smaller and yield a smaller denominator. Additionally, patients diagnosed in earlier years have longer follow-up and more time at risk than patients diagnosed more recently. Similarly, patients diagnosed in recent years have short follow-up and lower chance of death from any cause. A competing risk analysis was not carried out, as this was not the purpose of the current study. We included all patients in the SEER registry to reduce the risk of additional bias in selecting patients with a minimum follow up.
Conclusions
The risk of death from index-and nonindex-cancers varies widely among primary sites. Risk of specific noncancer deaths is substantial, particularly in the year after diagnosis. Patients with cancer of the lung, pancreas, and brain are most likely to die of their cancer. These sites may benefit from additional research funding. Second cancers are important causes of death for patients with cancers of the oropharynx, testis, larynx, and HL; these patients may benefit from more effective surveillance. Patients with breast and prostate cancer are at highest risk of noncancer death. Heart disease, whether from treatment or age, is an important cause of death, as is infection (probably due to treatment).
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